Share Search
Visit the Share Search
Oxford/AstraZeneca Covid-19 drug trial paused as participant falls ill
9th Sep 2020 07:53
(Sharecast News) - Final trials for a potential coronavirus vaccine being developed by AstraZeneca and Oxford University, have been paused after a participant had an adverse reaction in the UK.
AstraZeneca described it as a "routine action which has to happen whenever there is a potentially unexplained illness in one of the trials".
The AstraZeneca-Oxford University vaccine is among more than 160 being developed globally to fight the pandemic.
An individual familiar with the development told the health website Statnews that researchers had been told the hold was placed on the trial out of "an abundance of caution."
A second individual familiar with the matter, who also spoke to Statnews on condition of anonymity, said the finding is having an impact on other AstraZeneca vaccine trials underway - as well as on the clinical trials being conducted by other vaccine manufacturers.
Its move to Phase 3 testing in recent weeks has involved some 30,000 participants in the US as well as in the UK, Brazil and South Africa.
AstraZeneca described it as a "routine action which has to happen whenever there is a potentially unexplained illness in one of the trials".
The AstraZeneca-Oxford University vaccine is among more than 160 being developed globally to fight the pandemic.
An individual familiar with the development told the health website Statnews that researchers had been told the hold was placed on the trial out of "an abundance of caution."
A second individual familiar with the matter, who also spoke to Statnews on condition of anonymity, said the finding is having an impact on other AstraZeneca vaccine trials underway - as well as on the clinical trials being conducted by other vaccine manufacturers.
Its move to Phase 3 testing in recent weeks has involved some 30,000 participants in the US as well as in the UK, Brazil and South Africa.